Cardiovascular Disease Models

BioVenic provides high-quality, custom cardiovascular fish models to generate precise digital data for in vivo molecular target verification. Studying the biological networks behind cardiac development and vascular pathologies is fundamental to developing effective treatments for widespread human circulatory disorders. Compared with traditional rodent systems, aquatic models can faithfully recapitulate human cardiovascular abnormalities, featuring superior adaptability and scalability to support reliable cardiovascular screening and research validation.

Strategic Research Programs We Accelerate

• Academic and Clinical Cardiologists investigating fundamental embryonic heart patterning, cardiomyocyte cell signaling, and the evolutionary origins of functional tissue regeneration.
• Preclinical Drug Discovery Operations seeking high capacity, whole organism assay platforms to screen expansive compound libraries for novel cardioprotective or anti arrhythmic activity.
• Ecotoxicological Safety Agencies evaluating the developmental effects of aquatic contaminants, agricultural runoff, and heavy metals on early cardiac morphogenesis.

Fig 1. Zebrafish disease models for research on heart-related diseases.^1,3

Navigating Core Hurdles in Cardiovascular Modeling

• Bypassing the Rodent Screen Bottleneck: Replacing slow, capital intensive mammalian testing with rapid, high capacity phenotypic screening arrays.
• Resolving Deep Tissue Imaging Limits: Exploiting the natural optical clarity of early embryonic stages to capture ventricular contraction and vascular flow dynamics in real time without invasive procedures.
• Replicating Complex Human Cardiomyopathies: Establishing robust, stable genetic lines that exhibit definitive cellular pathologies like heart failure or heart chamber hypertrophy.
• Standardizing Circulatory Baseline Metrics: Ensuring absolute data reproducibility by maintaining highly uniform environmental and nutritional parameters across all cohorts.

Customized Aquatic Cardiovascular Modeling Services

• Myocardial Injury and Heart Regeneration Assays

Applicable Scenarios: Tracking tissue repair mechanisms and functional ventricular recovery after acute physical trauma.

Technical Capabilities: We perform localized laser or thermal cardiac ablation inside adult teleost fish under controlled therapeutic regimens to stimulate endogenous repair cascades.

Deliverables: High resolution video files recording ventricular recovery kinetics, localized gene transcript maps, and quantitative structural recovery dossiers.

• Dilated Cardiomyopathy and Chamber Hypertrophy Models

Applicable Scenarios: Investigating structural sarcomere disorganization, thin ventricular walls, and clinical cardiomyopathy pathways.

Technical Capabilities: Utilizing pre assembled nucleases, we induce targeted mutations in key structural loci, generating stable lines with defined pathological traits.

Deliverables: Digital cross sectional myocardial density maps, sarcomere alignment tracking logs, and allele copy number assay profiles.

• Cardiac Electrophysiology and Conduction Profiling

Applicable Scenarios: Screening candidate anti arrhythmic molecules and mapping early pacemaker signal transmission.

Technical Capabilities: We employ specialized optical voltage sensors and ultra high speed digital recording arrays to measure action potentials in transparent larvae.

Deliverables: Quantitative electrocardiographical signal plots, atrial ventricular beat synchronization sheets, and baseline rhythm variation metrics.

• Targeted Transgenesis for Vascular Labeling

Applicable Scenarios: Constructing custom fluorescent reporter systems to trace real time vessel branching and cell migration.

Technical Capabilities: Integrating single copy fluorescent expression cassettes driven by heart specific promoters like myl7 using active transposon vectors.

Deliverables: Complete plasmid sequence verification logs, high resolution spatial fluorescence imaging datasets, and genetic inheritance tracking charts.

• Pharmacological Induction and Cardiotoxicity Assays

Applicable Scenarios: Testing compound efficacy, determining dose response safety limits, and predicting potential side effects early in development.

Technical Capabilities: Administering candidate drugs via precise embryo water immersion or microinjection to monitor systemic physiological changes.

Deliverables: Digital drug accumulation curves, dose response survival indices, and automated cardiac functional metric logs.

• Specialized Surgical Ablation and Vascular Clotting Models

Applicable Scenarios: Studying cellular responses to acute localized infarcts, tissue ischemia, and local tissue transplants.

Technical Capabilities: Executing precise localized laser micro ablation or focal physical vessel occlusion to induce acute localized tissue lesions in adult hosts.

Deliverables: Post ablation tissue recovery metrics, spatial vascular clotting density maps, and quantitative digital tissue reconstruction dossiers.

Chronological Workflow from Model Design to Digital Delivery

Our systematic model development and characterization pipeline is optimized to deliver publication ready datasets and high fidelity translational insights.

1. Computational Strategy and Design: Designing target specific vectors and selecting the ideal host species through in silico homology alignments.
2. Model Target Induction: Executing precision transgenesis, pharmacological administration, or micro surgical ablation to initiate the desired disease state.
3. Controlled Environmental Husbandry: Rearing the induced cohorts under highly standardized aquatic conditions to guarantee uniform phenotypic development.
4. High Speed Optical Profiling: Capturing live, high resolution video files and fluorescent datasets of active cardiac contraction and vascular flow.
5. Molecular and Biochemical Assays: Performing quantitative polymerase chain reaction and Western blot assays to verify target biomarker upregulation.
6. Secure Digital Dataset Transfer: Delivering the complete, publication ready validation dossier, containing raw sequences, analytical charts, and imaging portfolios.

Strategic Advantages of Our Cardiovascular Modeling Platform

• High Evolutionary Homology: Capitalizing on the close physiological similarities and comparable resting heart rates shared between teleost fish and humans.
• In Vivo Optical Clarity: Exploiting transparent larval windows to perform live, non-invasive spatial tracking of structural heart defects and circulatory pathways.
• Diffusion Enabled Viability: Leveraging the unique ability of early larvae to obtain oxygen solely through passive diffusion, allowing functional characterization of otherwise lethal mutations.
• Exceptional Screen Efficiency: Harnessing high fecundity and rapid development to screen expansive candidate chemical libraries with high statistical power.

Strategic Applications of Aquatic Cardiovascular Models

• Investigating Regenerative Tissue Plasticity

Mapping the molecular signals that trigger functional myocardial repair after severe injury. Researchers utilize these models to discover the cellular switches that coordinate scarless healing, providing vital translational pathways for clinical cardiac therapies.

• Preclinical Safety and Cardiotoxicity Profiling

Conducting rapid, whole organism evaluations of extensive chemical libraries to analyze drug safety. Our automated systems screen compound effects on heart rate, rhythm, and contractility, optimizing drug candidates before initiating costly mammalian trials.

• Deciphering Genetic Bases of Cardiomyopathy

Replicating human mutations linked to dilated cardiomyopathy, ventricular thinning, or hypertrophic disorders. These customized systems allow investigators to trace how defined genotypes alter sarcomeric structure, chamber dimension, and systemic circulation.

• Biosensing Environmental Toxins

Monitoring the cardiotoxic impacts of water contaminants, agricultural pesticides, and heavy metals on embryonic heart development. Public health groups track how low dose toxic exposure causes valve failure and vascular patterning defects.

Published Data on Aquatic Cardiovascular Models

Recent literature highlights the translation of genetic mutations into predictable vascular dysplasia phenotypes in zebrafish (Danio rerio). Crossing the heg1∆25 mutant with the fluorescent reporter line Tg(flk1:eGFP) produced a bi genic line showing severe vascular malformations and blood stagnation. In mutant embryos, blood accumulated and coagulated within heart chambers, the posterior cardinal vein, and the tail vein, accompanied by dilation of the dorsal aorta lumen at 96 hours post fertilization. Quantitative software analysis validated that red blood cell movement in the tail vein was almost completely abolished, while qRT-PCR confirmed that thrombotic markers f2 and tbxasl were abnormally upregulated.

BioVenic actively builds on these published findings to continuously refine its target screening assays, optimize injection parameters, and enhance the overall translational value of our custom cardiovascular disease models.

Fig 2. heg1 deficiency leaded to poor blood flow and abnormal vascular development in zebrafish embryos.^2,3

Frequently Asked Questions

1. How do you validate the correlation between aquatic heart rate and human cardiac physiology?
   We focus on evolutionary conserved pacemaker structures, ion channel profiles, and neural regulation systems. Essential physiological landmarks like the sinoatrial node, atrium, ventricle, and cardiac valves are highly conserved between zebrafish and humans. We utilize in silico sequence alignments to verify target pathway homology before starting any modeling project.
2. What surgical methods are used to induce cardiac injury or heart failure in adults?
   We employ highly refined micro surgical interventions depending on your experimental objectives. These primarily include localized thermal cryoinjury or physical micro ventricular resection to trigger endogenous muscular repair mechanisms, as well as focal physical vessel occlusion to study ischemic cellular responses.
3. How are cardiovascular metrics such as ejection fraction measured in larval models?
   We utilize state of the art automated digital tracking and optical analysis systems. By recording high speed videos of cardiac contractions under high resolution microscopy, our specialized software calculates ventricular chamber volume dynamics, calculating fractional shortening, ejection fraction, and stroke volume automatically.

Partner with BioVenic

BioVenic is committed to boosting innovative progress in aquatic pathophysiology research through professional aquatic animal cardiovascular disease models. We understand that high-fidelity cardiovascular models are essential for studying vascular pathogenesis, testing therapeutic compounds, and analyzing cardiac functions in aquatic organisms. Our experienced technical team offers tailored and standardized model construction to meet your diverse research needs. To discuss your specific project requirements, explore our technical capabilities, or receive a detailed quote for your study, please contact us. Our professional team is ready to support your cardiovascular research and drive new scientific breakthroughs.

Our products and services are for research use only and cannot be used for any clinical purposes.

Related Services